Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.

Summary: Recovering from a heart attack involves more than just stabilizing the heart; it involves healing the blood vessels. In a recent study involving 95 heart attack survivors, researchers tested powerful cholesterol-lowering drugs known as PCSK9 inhibitors (alirocumab and evolocumab). Over six months, they tracked the thickness of the patients' carotid artery walls—a key measure of plaque buildup—and monitored tiny genetic markers called microRNAs.

The findings were promising: as the artery walls thinned (indicating plaque regression), levels of specific microRNAs dropped significantly. This suggests that these genetic markers could serve as a "blood test" to tell doctors if the arteries are physically healing, offering a new way to monitor recovery without invasive procedures.